PRME Stock Overview
A biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Prime Medicine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.94 |
| 52 Week High | US$9.80 |
| 52 Week Low | US$2.56 |
| Beta | 1.89 |
| 1 Month Change | -11.98% |
| 3 Month Change | -15.03% |
| 1 Year Change | -69.21% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -80.87% |
Recent News & Updates
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Dec 19
Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies
Nov 26Prime Medicine's Promising Pipeline: PM359 And Cash Burn Concerns
Sep 04Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Situation
Sep 04Prime Medicine Stock: Only For The Most Patient Of Investors
Jun 20Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?
May 14Recent updates
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Dec 19Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies
Nov 26Prime Medicine's Promising Pipeline: PM359 And Cash Burn Concerns
Sep 04Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Situation
Sep 04Prime Medicine Stock: Only For The Most Patient Of Investors
Jun 20Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?
May 14Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing
Jan 28Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Aug 25We're Not Very Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Rate
May 12Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?
Jan 24Shareholder Returns
| PRME | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.4% | 2.1% | 2.8% |
| 1Y | -69.2% | -3.8% | 24.5% |
Return vs Industry: PRME underperformed the US Biotechs industry which returned -3.8% over the past year.
Return vs Market: PRME underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| PRME volatility | |
|---|---|
| PRME Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PRME's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PRME's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 234 | Keith Gottesdiener | primemedicine.com |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.
Prime Medicine, Inc. Fundamentals Summary
| PRME fundamental statistics | |
|---|---|
| Market cap | US$352.16m |
| Earnings (TTM) | -US$219.25m |
| Revenue (TTM) | US$800.00k |
468.9x
P/S Ratio-1.7x
P/E RatioIs PRME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRME income statement (TTM) | |
|---|---|
| Revenue | US$800.00k |
| Cost of Revenue | US$162.64m |
| Gross Profit | -US$161.84m |
| Other Expenses | US$57.41m |
| Earnings | -US$219.25m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.72 |
| Gross Margin | -20,230.50% |
| Net Profit Margin | -27,406.12% |
| Debt/Equity Ratio | 0% |
How did PRME perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:39 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Prime Medicine, Inc. is covered by 17 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Samantha Lynn Semenkow | Citigroup Inc |